Table 3.
Chart review of patients with 25(OH)D ≥ 100 ng/mL
| |
|
|
|
Number of patients |
||||
|---|---|---|---|---|---|---|---|---|
| |
25(OH)D level (ng/ml) |
Number of patients |
Average age ± SD (yrs) |
Number of females |
Number of pediatric patients
a
|
Suspected cause of elevated 25(OH)D |
Hypercalcemia at time of 25(OH)D measurement |
|
| Over-the-counter vitamin D supplements | ||||||||
| UIHCb |
> 200 |
11 |
43.9 ± 18.3 |
5 (45.4%) |
1 (9.1%) |
4 (36.3%) |
4 (36.3%) |
0 |
| |
151 – 200 |
16 |
58.0 ± 19.6 |
10 (62.5%) |
2 (12.5%) |
4 (25.0%) |
6 (37.5%) |
2 (12.5%) |
| |
126 – 150 |
24 |
53.1 ± 17.4 |
18 (75.0%) |
0 |
6 (25.0%) |
6 (25.0%) |
1 (4.2%) |
| |
100 – 125 |
58 |
49.5 ± 20.0 |
38 (65.5%) |
2 (3.4%) |
6 (10.3%) |
4 (6.9%) |
0 |
| WCMC |
> 200 |
5 |
58.8 ± 21.5 |
4 (80.0%) |
0 |
1 (20%) |
3 (60%) |
4 (80%) |
| |
151 – 200 |
10 |
46.0 ± 14.9 |
7 (70.0%) |
0 |
3 (30%) |
4 (40%)c |
0 |
| |
126 – 150 |
6 |
58.8 ± 12.1 |
6 (100.0%) |
1 (16.7%) |
1 (16.7%) |
0d |
0 |
| 100 – 125 | 29 | 57.0 ± 16.8 | 25 (86.2%) | 0 | 4 (13.8%) | 10 (34.5%) | 0 | |
aAge < 18 years old.
bIncluding repeat measurements on patients, there were 16, 22, 27, and 75 total measurements in the > 100 ng/mL, 151–200 ng/mL, 1260–150 ng/mL, and 100–125 ng/mL categories, respectively.
cOne additional patient received monthly 50,000 IU Vitamin D doses, not listed as given by prescription.
dOne additional patient received “Vitamin B12 and D” injections (no doses listed), not listed as given by provider.